Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink

BMC Cardiovascular Disorders

Shah Ebrahim¹  Harriet Forbes¹  Liam Smeeth¹  Ian Douglas¹  Ana Filipa Macedo² 

[1] Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK;Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal

关键词: Observational;    Safety;    Cardiovascular;    Type 2 diabetes;    Statins;   

Others  :  1088487
DOI  :  10.1186/1471-2261-14-85

 received in 2014-07-02, accepted in 2014-07-07,  发布年份 2014

【 摘 要 】

Background

There is strong evidence of reductions in major vascular events from statins across all cardiovascular risk categories. However, trials of statin therapy have provided conflicting results regarding statin use and type 2 diabetes (T2DM). We aimed to assess the effect of statins on T2DM development.

Method

We carried out a population-based cohort study using the Clinical Practice Research Datalink (CPRD), a database of computerized clinical records. Every patient aged 30–85 years old starting a statin between 1989 and 2009 was matched with up to five non-statin users. The observation period in CPRD ended in 31 December 2011. Cox proportional hazard regression was used to compare rates of T2DM between statin users and non-users, using propensity score method to adjust for systematic differences between groups.

Results

The study basis comprised 2,016,094 individuals, including 430,890 people who received a statin, matched to 1,585,204 people not prescribed a statin. Mean follow-up time was 5.43 years for statin users and 3.89 years for nonusers. During follow-up 130,395 individuals developed T2DM. Statin use was associated with an increased risk of T2DM (HR 1.57; 95% CI 1.54-1.59), which increases with longer duration of use. The increased risk was smaller among people with hypertension or cardiovascular disease and was only apparent after 5 or more years treatment with statins in these groups. Conversely, age-specific risk ratios decreased in older people.

Conclusions

Statin use is associated with an increased risk of T2DM. Our results suggest that the relative risk is higher among people without diagnosed hypertension or cardiovascular disease. These findings should be considered in the context of the observational nature of the data which is prone to bias and unmeasured confounding.

【 授权许可】

   
2014 Macedo et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]A Report from the American Heart Association: Heart Disease and Stroke Statistics—2013 Update. Circulation 2013, 127:e6-e245.
• [2]European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2012, 33:1635-1701.
• [3]Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.
• [4]Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
• [5]Cholesterol Treatment Trialists' (CTT) Collaborators: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380(9841):581-590.
• [6]Collaborators CTT'(CTT): Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012, 7(1):e29849. Epub 2012 Jan 19
• [7]Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375(9716):735-742.
• [8]Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M: Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011, 104(2):109-124.
• [9]Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
• [10]Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
• [11]Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
• [12]Coleman CI, Reinhart K, Kluger J, White CM: The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008, 24:1359-1362.
• [13]Jick SS, Bradbury BD: Statins and newly diagnosed diabetes. Br J Clin Pharmacol 2004 Sep, 58(3):303-309.
• [14]Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y: Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012 Jan 23, 172(2):144-152.
• [15]Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, Chen TJ, Lin SJ, Chiang CE: Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012 Oct 2, 60(14):1231-1238.
• [16]Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, De Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305(24):2556-2564. 22
• [17]Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM: Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013, 346:f2610. doi:10.1136/bmj.f2610
• [18]Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P: Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011, 57(14):1535-1545.
• [19]Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB Sr: Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s. The Framingham Heart Study. Circulation 2006, 113:2914-2918.
• [20]Chen L, Magliano J, Zimmet PZ: The worldwide epidemiology of type 2 diabetes mellitus—present and future perspective. Nat Rev Endocrinol 2012, 8:228-236.
• [21]Meigs JB, The Kelly West Award Lecture 2009: Epidemiology of Type 2 Diabetes and Cardiovascular Disease: Translation From Population to Prevention. Diabetes Care 2010, 33:1865-1871.
• [22]Key health statistics from general practice 1998: Analyses of Morbidity and Treatment Data, Including Time Trends, England and Wales. Series MB6 no. 2. London: Office for National Statistics; 2000.
• [23]Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigómez A: Validity of the general practice research database. Pharmacotherapy 2003, 23:686-689.
• [24]Van Staa T-P, Abenhaim L: The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf 1994, 3:15-21.
• [25]Khan NF, Harrison SE, Rose PW: Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010, 60(572):e128-e136.
• [26]Rodríguez G, Pérez LA, Gutthann S: Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998, 45(5):419-425.
• [27]Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ: Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010 Jan, 69(1):4-14.
• [28]Brookhart M, Schneeweiss S, Rothman KJ, Glynn R, Avorn J, Sturner T: Variable selection for propensity score models. Am J Epidemiol 2006, 163:1149-1156.
• [29]Sturmer T, Rothman KJ, Avorn J, Glynn RJ: Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol 2010, 172:843-854.
• [30]Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, (Issue 1):CD004816. doi:10.1002/14651858.CD004816.pub4
• [31]Weycker D, Nichols GA, O'Keeffe Rosetti M, Edelsberg J, Vincze G, Khan ZM, Oster G: Excess risk of diabetes in persons with hypertension. J Diabetes Complications 2009, 23(5):330-336.
• [32]Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. J Med N Eng 2000, 342:905-912.
• [33]Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M, Burneck study: Population based incidence rates and risk factors for type 2 diabetes in white individuals. Diabetes 2004, 53:1782-1789.
• [34]Kannel WB: Blood pressure as a cardiovascular risk factor. J Am Med Assoc 1996, 275:1571-1576.
• [35]Kannel WB: Risk stratification in hypertension: New insights from the Framingham Study. Am J Hypertens 2000, 13:3S-10S.
• [36]Reaven GM, Chang H: Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in spontaneous hypertensive and Wistar-Kyoto rats. Am J Hypertens 1991, 4:34-38.
• [37]Reaven GM: Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 1991, 21:7S-12S.
• [38]Baker WL, Talati R, White CM, Coleman CI: Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87(1):98-107.
• [39]Koh KK, Sakuma I, Quon MJ: Differential metabolic effects of distinct statins. Atherosclerosis 2011, 215:1-8.
• [40]Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T: Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006, 49:1881-1892.
• [41]Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, Bruham LR, Verchere CB, Hayden MR: Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010, 53:1110-1119.
• [42]Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR: Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007, 13:340-347.
• [43]Brunham LR, Kruit JK, Hayden MR, Verchere CB: Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. Curr Diab Rep 2010 Feb, 10(1):55-60.
• [44]Orozco LJ, Buchleitner AM, Gimenez Perez G, Roqué I, Figuls M, Richter B, Mauricio D: Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, (3):CD003054. doi:10.1002/14651858.CD003054.pub3
• [45]Cardona-Morrell M, Rychetnik L, Morrell SL, Espinel PT, Bauman A: Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health 2010, 10:653. doi:10.1186/1471-2458-10-653
• [46]Ramlo-Halsted BA, Edelman SV: The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies. Clin Diab 2000, 18(2):80-85.
• [47]Pani LN, Nathan DM, Grant RW: Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care 2008, 31:386-390.
• [48]Nichols GA, Hillier TA, Brown JB: Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 2007, 30:228-233.
• [49]Fonseca VA: Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care 2009 November, 32(Suppl 2):S151-S156.
• [50]Van Staa TJ, Smeeth L, SW Ng E, Goldacre B, Gulliford M: The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? Heart Online First 2013. doi:10.1136/heartjnl-2013-303698